OxThera Presents Encouraging 52-Week Efficacy and Safety Data for Oxabact® in Primary Hyperoxaluria Type 1 (PH1) Patients with ESRD
OxThera AB, a Stockholm-based privately-held biopharmaceutical companyand leader in the field of microbiome derived biotherapeutics, today announced a poster presentation showing encouraging Oxabact® efficacy and safety data from the long-term study OC5-OL-01, at the Annual […]